TY - JOUR
T1 - Targeted molecular therapeutic options for hepatocellular carcinoma
AU - Sridhar, Swathi
AU - Sharma, Ishna
AU - Sankpal, Umesh T.
AU - Ghabach, Bassam
AU - Narra, Kalyani
AU - Neerukonda, Latha
AU - Basha, Riyaz
N1 - Funding Information:
RB and UTS are supported by NIMHD (Grant No. 2U54 MD006882-06) and NCI (Grant No. 1P20CA233355-01).
Publisher Copyright:
© 2020 by Begell House, Inc.
PY - 2020
Y1 - 2020
N2 - Liver cancer is the 6th leading cause of cancer related deaths in the US even though it ranks 14th in incidence. More men are diagnosed with liver cancer than women, and the number of projected deaths among men (20,020) is almost double that among women (10,140) in the US. Infections like hepatitis and metabolic conditions like obesity are believed to be major risk factors for the onset of liver cancer. Hepatocellular carcinoma (HCC), the most common type of liver cancer, accounts for 75% of all cases. Chemotherapy has not been effective in treating HCC. Targeted therapies are being used in advanced HCC patients due to a better survival and less side effects when compared to traditional chemotherapy. Therapeutic agents targeting the regulators of growth factor signaling pathways and the mediators of downstream signaling—for example, inhibitors of the tyrosine kinase receptor—are used as targeted molecular therapies. Kinase inhibitors that modulate growth signals, such as sorafenib and lenvatinib, are commonly employed in targeted molecular therapy for HCC patients. This review covers these agents, highlighting modes of action and providing details on clinical trials.
AB - Liver cancer is the 6th leading cause of cancer related deaths in the US even though it ranks 14th in incidence. More men are diagnosed with liver cancer than women, and the number of projected deaths among men (20,020) is almost double that among women (10,140) in the US. Infections like hepatitis and metabolic conditions like obesity are believed to be major risk factors for the onset of liver cancer. Hepatocellular carcinoma (HCC), the most common type of liver cancer, accounts for 75% of all cases. Chemotherapy has not been effective in treating HCC. Targeted therapies are being used in advanced HCC patients due to a better survival and less side effects when compared to traditional chemotherapy. Therapeutic agents targeting the regulators of growth factor signaling pathways and the mediators of downstream signaling—for example, inhibitors of the tyrosine kinase receptor—are used as targeted molecular therapies. Kinase inhibitors that modulate growth signals, such as sorafenib and lenvatinib, are commonly employed in targeted molecular therapy for HCC patients. This review covers these agents, highlighting modes of action and providing details on clinical trials.
KW - Hepatocellular carcinoma
KW - Lenvatinib
KW - Sorafenib
KW - Targeted molecular therapy
UR - http://www.scopus.com/inward/record.url?scp=85090107877&partnerID=8YFLogxK
U2 - 10.1615/CritRevOncog.2020034985
DO - 10.1615/CritRevOncog.2020034985
M3 - Article
C2 - 32865910
AN - SCOPUS:85090107877
SN - 0893-9675
VL - 25
SP - 47
EP - 55
JO - Critical Reviews in Oncogenesis
JF - Critical Reviews in Oncogenesis
IS - 1
ER -